completes

Johnson & Johnson Vision Completes Acquisition of Device Manufacturer TearScience

SANTA ANA, Calif.—Johnson Johnson Vision has completed its previously announced acquisition of TearScience Inc., a medical device manufacturer that focuses on evaluating meibomian gland health and treating Meibomian Gland Dysfunction (MGD), the leading cause of dry eye disease. In an announcement earlier this week, JJ Vision said the transaction represents another step in its strategy to become “a broad-based, global leader in eye health and further expands the company’s leading eye health portfolio.” In addition, JJ Vision noted that the acquisition marks its expansion into dry eye medical device technology and provides “a complementary eye health solution to address an…


TearClear Completes $4.5 Million Series A Financing and Introduces Leadership Team

ORANGE COUNTY, Calif.—TearClear Corp., an early-stage, eye health technology company, reported Tuesday that it completed a Series A financing round that generated proceeds of $4.5 million. Visionary Venture Fund and Bluestem Capital were the co-leaders of the funding round, according to the announcement. The financing will provide sufficient capital to advance development of TearClear’s filter technology, which the start-up says is the first and only system to “assure the safe delivery of a preservative-free drop from preserved, multi-dose products.” TearClear is focused on developing a safe and reliable means of delivering preservative-free topical ophthalmic drugs, the company says. In addition,…


Sun Pharma Completes Acquisition of Ocular Technologies Sarl

NEW DELHI—Sun Pharmaceutical Industries announced that it has completed the acquisition of U.S.-based eyecare specialist Ocular Technologies Sarl, a portfolio company of Auven Therapeutics. As VMail previously reported, Sun Pharma was set to pay Auven $40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on Seciera sales, which is currently in Phase-3 confirmatory clinical trials. “All the necessary formalities for closure of the said transaction have been concluded and the company has successfully completed the acquisition of Ocular Technologies Sarl, on December 15, 2016,” Sun Pharmaceutical Industries said in a BSE filing.


No Picture

Sun Pharma Completes Acquisition of Ocular Technologies Sarl

NEW DELHI—Sun Pharmaceutical Industries announced that it has completed the acquisition of U.S.-based eyecare specialist Ocular Technologies Sarl, a portfolio company of Auven Therapeutics. As VMail previously reported, Sun Pharma was set to pay Auven $40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on Seciera sales, which is currently in Phase-3 confirmatory clinical trials. “All the necessary formalities for closure of the said transaction have been concluded and the company has successfully completed the acquisition of Ocular Technologies Sarl, on December 15, 2016,” Sun Pharmaceutical Industries said in a BSE filing.


Canada’s New Look Vision Group Completes Purchase of British Columbia Retailer

Antoine Amiel.​ MONTREAL, QUEBEC—New Look Vision Group Inc. (BCI.TO) has completed its planned acquisition of the retail optical assets and business portion of western Canadian retailer Visions One Hour Optical Ltd., according to a statement New Look Vision Group issued Tuesday. Visions One Hour Optical, based in Abbotsford, British Columbia, operates principally under the Visions Optical banner in local communities at 10 retail locations across the Canadian province, according to the statement. As VMail reported in October when the deal was first announced, Visions One Hour Optical had estimated revenue of $5.2 million in the 12-month period ended July 31,…